Clinical Trial Update: Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older [Phase 4]

View source ↗

Summary

Phase 4 trial update of afatinib for EGFR mutation-positive non-small cell lung cancer in patients aged 70 or older; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung, ErbB Receptors | Phase 4 | Status: COMPLETED | Results posted: 2020-03-30